Mersana Therapeutics, Inc.
MRSN
$0.40
-$0.0329-7.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.36M | 12.60M | 2.29M | 9.25M | 10.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.36M | 12.60M | 2.29M | 9.25M | 10.70M |
| Cost of Revenue | 22.29M | 14.80M | 17.25M | 18.69M | 21.50M |
| Gross Profit | -5.93M | -2.21M | -14.95M | -9.44M | -10.79M |
| SG&A Expenses | 8.89M | 9.86M | 10.50M | 11.56M | 10.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.17M | 24.67M | 27.75M | 30.25M | 31.63M |
| Operating Income | -14.81M | -12.07M | -25.46M | -21.00M | -20.93M |
| Income Before Tax | -14.12M | -11.08M | -24.27M | -19.31M | -19.54M |
| Income Tax Expenses | 0.00 | 418.00K | -- | -- | -- |
| Earnings from Continuing Operations | -14.12M | -11.50M | -24.27M | -19.31M | -19.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.12M | -11.50M | -24.27M | -19.31M | -19.54M |
| EBIT | -14.81M | -12.07M | -25.46M | -21.00M | -20.93M |
| EBITDA | -14.41M | -11.67M | -25.05M | -20.58M | -20.48M |
| EPS Basic | -0.11 | -0.09 | -0.20 | -0.16 | -0.16 |
| Normalized Basic EPS | -0.07 | -0.06 | -0.12 | -0.10 | -0.10 |
| EPS Diluted | -0.11 | -0.09 | -0.20 | -0.16 | -0.16 |
| Normalized Diluted EPS | -0.07 | -0.06 | -0.12 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 123.56M | 122.72M | 122.44M | 121.43M | 120.61M |
| Average Diluted Shares Outstanding | 123.56M | 122.72M | 122.44M | 121.43M | 120.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |